The first batch of about 770,000 doses of Fubita bivalent vaccine has arrived in Hong Kong. Online appointments for vaccination were opened yesterday (27th). Eligible citizens can start receiving the Fubita bivalent vaccine from Thursday (1st).
The Secretary of the Civil Service Bureau, Yang He Beiyin, said today (28th) that there are currently about 11,600 people who have made appointments for vaccination.
Cui Junming, president of the Hong Kong Society of Hospital Pharmacists, said that compared with the original vaccine, the bivalent vaccine of Fubitai has a 3.2 to 4.8 times higher level of neutralizing antibodies, and can be stored at 30 degrees for 12 hours without dilution.
He believes that the bivalent vaccine can be extended to the outreach of residential care homes, and suggested that the government can relax the third dose of vaccination for the elderly to increase the vaccination rate.
▼November 9th, BB version of Fubitai started today Parents take their children to Children's Hospital for injection▼
Yang He Beiyin said in the Hong Kong and Taiwan program "Millennium Times" that since the appointment of the bivalent vaccine was opened yesterday, there are currently about 11,600 people who have made appointments for vaccination. She believes that the number is within expectations, because citizens hope to obtain comprehensive protection.
Although there is no statistics on the age group of the appointment, since the government recommends that all citizens over the age of 50 be vaccinated, she expects the proportion of this age group to be relatively high.
Yang He Beiyin: The research institute supplies bivalent vaccines
At present, the government has ordered a total of 1.9 million doses from pharmaceutical companies. Based on the number of people receiving the third dose of vaccine in Hong Kong, she believes that the quantity is sufficient, and will make arrangements depending on the arrival time of the bivalent vaccine.
As for whether the first dose of the bivalent vaccine can be vaccinated, she said that "it should not be used for the first dose", and the other doses are subject to discussion by experts for further research.
She also said that it is temporarily difficult for the outreach vaccination service in residential care to provide bivalent vaccines due to high storage requirements and the need for dilution.
However, she also pointed out that the outreach vaccination still supplies the original vaccine, and the bivalent vaccine needs further research. If the delivery difficulty can be overcome, she stressed that "it will definitely be done."
Cui Junming: The antibody level of the bivalent vaccine is 4.8 times higher than the original
Cui Junming said in the same program that compared with the original vaccine, Fubitai’s bivalent vaccine is more effective against the Omicron branch, and the neutralizing antibody level is 3.2 to 4.8 times higher, while the side effects are the same.
He pointed out that the first batch of citizens who received the third dose of the vaccine has been inoculated for almost 6 months, and the level of neutralizing antibodies will decrease. At the same time, they can leave Hong Kong for travel.
The government does not require children under the age of 12 to receive bivalent vaccines. He believes that the government considers manpower arrangements, storage and transportation, and dosage issues. He also pointed out that the United States currently allows children over the age of 5 to receive bivalent vaccines.
He believes that if the response to the bivalent vaccine is good, the 1.9 million doses ordered by the government will not be enough.
New crown vaccine: The picture shows a photo released by the Associated Press on August 26, 2022, showing the packaging of a new version of the bivalent new crown vaccine in a Michigan factory in the United States. The vaccine was developed by the American pharmaceutical company Pfizer and the German biotech company BioNTech. It targets the new crown Virus variant strains Omicron subtypes BA.4 and BA.5, while protecting against the original strain.
(AP)
"After vaccination with Kexing, you can receive Fubitai bivalent vaccine"
Cui Junming also pointed out that the bivalent vaccine can be provided to institutions or home outreach, because the bivalent vaccine can be stored at 30 degrees for 12 hours before opening the bottle, and there is no need to dilute; as for the original vaccine, it can only be used for 2 hours. .
Therefore, he believes that 12 hours is enough to vaccinate in nursing homes and homes.
He also cited foreign research that different brands of vaccines can be used in different injections. He believed that after receiving the Sinovac vaccine, he could also receive the bivalent vaccine of Fubitai.
He also pointed out that Singapore stipulates that any age group can be vaccinated with the bivalent vaccine in the first dose. He thinks that the elderly can be vaccinated with the bivalent vaccine in the third dose. It is believed that the family members of the elderly can increase the vaccination rate after knowing that the protection rate is higher.
▼On September 22, Lu Chongmao and officials received the fourth dose of Sinovac vaccine and flu vaccine▼
+3
The bivalent vaccine can be vaccinated over the age of 12
Fubitai bivalent vaccine can be used by eligible persons aged 12 or above as the fourth dose of the vaccine or as an alternative to the third dose of the recovered person according to the current vaccination schedule, but they can still choose to receive Sinovac or Fubitai original strain vaccine.
Three types of people are eligible to receive Fubitai Bivalent Vaccine:
1) People aged 50 or above.
2) Immunocompromised persons aged 12 or above.
3) People aged 18 to 49 consider their own risks and benefits, such as higher exposure risks or personal needs, including nursing homes, medical institutions, port staff and cross-border drivers.
From 12.1, the fourth dose of Fubitai bivalent vaccine is optional About 770,000 doses have been approved to arrive in Hong Kong. The government intends to vaccinate citizens with bivalent vaccines starting in December. Rihua: It can strengthen immunity against mutant viruses
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/2C5HI6YHNFHDLJSBNWHOIAS2AE.jpeg)
